15997-89-4 Usage
Uses
4,5-Dichlorophthalimide (5,6-dichloro-1H-isoindole-1,3(2H)-dione) is suitable as a reactant in the synthesis of 5′-N-(4′′,5′′-dichlorophthaloyl)-3′-azido-2′,3′-dideoxythymidine and 2-amino-4,5-dichlorobenzoic acid.It may be used in the following studies:As a reactant in the synthesis of 4,5-dichloro-1,2-benzenedicarboxamide.As an additive in the Ir-BICP catalyzed asymmetric hydrogenation of 2,3,3-trimethylindolenine to improve enantioselectivity.As a reactant in the synthesis of octachloro-Cu-phthalocyanine.As a reagent in the synthesis of 7-tert-butylthianthrene-2,3-dicarboxylic imide.As a starting material in the synthesis of N-(3-bromopropyl)-4,5-dichlorophthalimide.As a nucleophilic partner in the phosphine-catalyzed allylic substitution of Morita-Baylis-Hillman acetates to form N-protected β-amino phosphonic acid esters.
General Description
4,5-Dichlorophthalimide (5,6-dichloro-1H-isoindole-1,3(2H)-dione) is a phthalimide derivative. It has been synthesized from 5,6-dichloro-1,3-isobenzofurandione and characterized by 1H ,13C-NMR and IR. The dipole moment, polarizability and first-order hyperpolarizability of 4,5-dichlorophthalimide have been investigated using ab initio and density functional theory calculations.
Check Digit Verification of cas no
The CAS Registry Mumber 15997-89-4 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,5,9,9 and 7 respectively; the second part has 2 digits, 8 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 15997-89:
(7*1)+(6*5)+(5*9)+(4*9)+(3*7)+(2*8)+(1*9)=164
164 % 10 = 4
So 15997-89-4 is a valid CAS Registry Number.
InChI:InChI=1/C8H3Cl2NO2/c9-5-1-3-4(2-6(5)10)8(13)11-7(3)12/h1-2H,(H,11,12,13)
15997-89-4Relevant articles and documents
ADAMTS INHIBITORS, PREPARATION METHODS AND MEDICINAL USES THEREOF
-
Page/Page column 86, (2021/08/13)
Compounds of formula (I) useful as inhibitors of ADAMTS-5 and/or ADAMTS-4, pharmaceutical compositions thereof, and use of them as therapeutic agents for the treatment of diseases involving degradation of cartilage or disruption of cartilage homeostasis, in particular osteoarthrosis and/or rheumatoid arthritis, are disclosed.
Grinding imidation of anhydrides on smectite clays as recyclable and heterogeneous catalysts under solvent-free conditions
Marvi, Omid
, p. 3501 - 3504 (2017/08/14)
Imidation of various anhydrides employing solvent-free grindstone technique using smectite clays as recyclable and green catalysts was examined and obtained excellent yields.
Discovery of novel dual-action antidiabetic agents that inhibit glycogen phosphorylase and activate glucokinase
Zhang, Lei,Chen, Xiaojie,Liu, Jun,Zhu, Qingzhang,Leng, Ying,Luo, Xiaomin,Jiang, Hualiang,Liu, Hong
, p. 624 - 639 (2013/02/21)
Dual-target-directed agents simultaneously inhibiting glycogen phosphorylase (GP) and activating glucokinase (GK) could decelerate the inflow of glucose from glycogenolysis and accelerate the outflow of glucose in the liver, therefore allow for a better control over hyperglycaemia in a synergetic manner. A series of hybrid compounds were designed by structure-assisted and ligand-based strategies. In vitro bioassays found two novel compounds (1j, 6g) worthy of further optimization on balance of dual action to GP and GK. In addition, for single-target activity, two compounds exhibited more potent GP inhibitory activity and four compounds showed better GK activation than their corresponding references.
